Assignee
TOLREMO THERAPEUTICS AG
CH·3 granted patents·7 pending applications·0 citations·filing 2018–2025
Top patents by PatentIndex Score
10 records- 0165US2026076967A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0257US12595258B2Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2025·Granted Apr 7, 2026·0 cites·4 claims
- 0351US2025289818A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancerTOLREMO THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0450US2024327394A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0550US2023067929A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancerTOLREMO THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 0647US12478624B2Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2020·Granted Nov 25, 2025·0 cites·8 claims
- 0747US12472179B2Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancerTOLREMO THERAPEUTICS AG·Filed 2021·Granted Nov 18, 2025·0 cites·18 claims
- 0839US2023255966A1A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclcTOLREMO THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 0939US2023226057A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic diseaseTOLREMO THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1036US2020325543A1Diagnostic methodTOLREMO THERAPEUTICS AG·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →